Michael Flanagan, MD
Urology · Middlebury, CTNPI 1902860166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,265 and has fallen 72.1% since, to $353 in 2025.
Across 257 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$833
- Johnson & Johnson$501
- C. R. Bard, Inc. & Subsidiaries$425
- Pfizer$406
- Sumitomo Pharma America, Inc.$399
- Bayer$334
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,45593%
- Education$4427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 44 | $833 |
| Johnson & Johnson | 30 | $501 |
| C. R. Bard, Inc. & Subsidiaries | 10 | $425 |
| Pfizer | 22 | $406 |
| Sumitomo Pharma America, Inc. | 16 | $399 |
| Bayer | 17 | $334 |
| Dendreon Pharmaceuticals LLC | 9 | $261 |
| AbbVie(2 entities) | 13 | $249 |
| Progenics Pharmaceuticals, Inc. | 3 | $242 |
| Amgen | 9 | $227 |
| Acerus Pharmaceuticals Corporation | 10 | $195 |
| Bard Access Systems, Inc. | 2 | $145 |
| Boston Scientific | 2 | $138 |
| Tolmar, Inc. | 5 | $126 |
| Novartis | 4 | $109 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Tolmar Pharmaceuticals, Inc. | 5 | $97 |
| Aytu Biopharma, Inc. | 6 | $95 |
| Urogen Pharma, Inc. | 4 | $94 |
| Myovant Sciences Inc. | 4 | $85 |
| Teleflex LLC | 4 | $83 |
| Inspire Medical Systems, Inc. | 1 | $79 |
| Endo Pharmaceuticals Inc. | 5 | $73 |
| Dentsply IH Inc. | 4 | $68 |
| Coloplast | 4 | $61 |
| Urovant Sciences Inc | 3 | $60 |
| Myriad Genetic Laboratories, Inc. | 3 | $53 |
| Ferring Pharmaceuticals Inc. | 3 | $48 |
| Antares Pharma, Inc. | 2 | $48 |
| 180 Medical, Inc. | 2 | $43 |
| Shockwave Medical, Inc | 1 | $41 |
| Accord Healthcare, Inc. | 2 | $40 |
| Telix Pharmaceuticals | 1 | $26 |
| Palette Life Sciences, Inc. | 1 | $26 |
| Medtronic | 1 | $24 |
| Sanofi | 1 | $21 |
| Mission Pharmacal Company | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $14 |
| Avanos Medical | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,897 in reported general payments places this provider in the 75th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 17 | $248,398 |
| GemtesaVibegron | 222 | $223,676 |
| MyrbetriqMirabegron | 80 | $90,899 |
| ElmironPentosan Polysulfate Sodium | 12 | $28,830 |
| Tamsulosin Hcl | 976 | $13,783 |
| Mirabegron ErMirabegron | 12 | $9,502 |
| Finasteride | 545 | $6,195 |
| Dutasteride | 137 | $5,148 |
| Doxazosin Mesylate | 333 | $4,146 |
| Tadalafil | 17 | $2,677 |
| Testosterone | 12 | $2,538 |
| Oxiconazole Nitrate | 11 | $2,259 |
| Silodosin | 14 | $2,065 |
| NitrofurantoinNitrofurantoin Macrocrystal | 27 | $1,792 |
| Testosterone Cypionate | 52 | $1,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $833 | $339,29797 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $399 | $223,676222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 urology providers in Connecticut.
Other urology in Middlebury
- York MoyMiddlebury$16K
- Anthony KimMiddlebury$14K
- Sagar PhatakMiddlebury$8K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.